Huahai Pharmaceutical: Fluvastatin Sodium Sustained-Release Tablets and Pimecrolimus Cream have obtained drug registration certificates.

Hua Hai Pharmaceutical announced that it has recently received the "Drug Registration Certificate" for the sustained-release tablets of pitavastatin sodium and the cream of pimecrolimus issued by the National Medical Products Administration. The sustained-release tablets of pitavastatin sodium are used for patients with primary hypercholesterolemia and mixed dyslipidemia whose diet is not fully controlled. The domestic market sales amount to approximately 144 million RMB, with a research and development investment of about 10.44 million RMB. The pimecrolimus cream is used for patients with mild to moderate atopic dermatitis without immune impairment for 3 months and above. The domestic market sales amount to approximately 294 million RMB, with a research and development investment of about 6.89 million RMB. The approval of these products further enriches the company's product line and helps enhance the company's market competitiveness.